Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .
Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement.
OBJECTIVES Interstitial cystitis ( IC ) is a chronic , debilitating condition that is often associated with late diagnosis and a delay in initiation of appropriate IC-specific therapy . The purpose of this study was to determine whether the length of time from initial diagnosis to start of treatment impacts subsequent symptom improvement . METHODS A retrospective analysis was conducted in 128 patients with IC who had been treated with pentosan polysulfate sodium ( PPS ) 300 mg/day for 32 weeks in a multicenter , r and omized , double-blind , parallel-group clinical trial . Outcome measures included the O'Leary-Sant Interstitial Cystitis Symptom Index ( ICSI ) and the O'Leary-Sant Interstitial Cystitis Problem Index ( ICPI ) . Early treatment was defined as treatment initiation 6 months or less after IC diagnosis , whereas late treatment was defined as treatment initiation 24 months or more after IC diagnosis . Efficacy data were analyzed by using the intent-to-treat , last-observation-carried-forward population . RESULTS At the end of the study , mean changes from baseline in total ICSI and ICPI scores ( + /- SEM ) for early treatment ( 6 months or less ) versus late treatment ( 24 months or more ) were 3.97 + /- 0.59 versus 2.15 + /- 0.70 ( P = 0.0472 ) and 3.94 + /- 0.56 versus 1.77 + /- 0.63 ( P = 0.0117 ) , respectively . Similar trends for both measures were observed when examining other times from IC diagnosis ( 3 months or less versus 24 months or more , 3 months or less versus 36 months or more , and 6 months or less versus 36 months or more ) . CONCLUSIONS Initiation of PPS treatment within 6 months of establishing the diagnosis of IC may be associated with greater improvement in patient symptoms and symptom bother
Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .